Quantbot Technologies LP Makes New Investment in Haemonetics Co. (NYSE:HAE)

Quantbot Technologies LP bought a new stake in Haemonetics Co. (NYSE:HAE) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,415 shares of the medical instruments supplier’s stock, valued at approximately $345,000.

Other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP increased its position in Haemonetics by 9.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after acquiring an additional 363,702 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Haemonetics by 14.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock valued at $98,716,000 after purchasing an additional 164,111 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Haemonetics by 1.8% in the third quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock valued at $95,986,000 after purchasing an additional 21,547 shares in the last quarter. Boston Trust Walden Corp raised its position in Haemonetics by 13.1% in the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after purchasing an additional 106,114 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Haemonetics by 0.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier’s stock valued at $62,802,000 after buying an additional 5,668 shares during the period. 99.67% of the stock is owned by institutional investors.

Haemonetics Trading Down 1.8 %

Shares of NYSE HAE opened at $63.03 on Friday. Haemonetics Co. has a twelve month low of $58.80 and a twelve month high of $97.97. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of 24.81, a P/E/G ratio of 1.11 and a beta of 0.43. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The company’s fifty day moving average is $66.05 and its 200-day moving average is $74.68.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities research analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on HAE shares. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Bank of America downgraded shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $95.00 to $68.00 in a research report on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 price target for the company. Needham & Company LLC cut their price objective on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Finally, Raymond James reaffirmed a “strong-buy” rating and set a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Haemonetics currently has an average rating of “Moderate Buy” and a consensus target price of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.